Abstract
Background: 21 novel 1-alkoxy-1H-benzo[d]-1,2,3-triazole compounds were designed, prepared and evaluated for their antidepressant and anticonvulsant effects in mice.
Method: Compound 19 significantly decreased immobility time in the FST without altering the locomotor activity in the open field test, and exhibited higher levels of efficacy than the reference standard fluoxetine. Compound 19 significantly increased 5-HT, NE and 5-HIAA levels in mice brain, implying that the antidepressant activity might be mediated by these neurotransmitters. In the seizure test, compound 19 also showed better anticonvulsant activity against MES, whereas had not shown neurotoxicity (300 mg/kg). Conclusion: Our data indicated that compound 19 could potentially be used as the antidepressant drug in patients with epilepsy.Keywords: Benzo[d]-1, 2, 3-triazole, FST, neurotransmitters, MES, antidepressant.
Graphical Abstract
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Computer-Aided Drug Design
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Related Books
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
New Avenues in Drug Discovery and Bioactive Natural Products
Practice and Re-Emergence of Herbal Medicine
33
2